ScholarIQanswers from OpenAlex & ORCID
Niels Jongs
ResearcherPublications, citations & collaboration network
Niels Jongs is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Niels Jongs have?
ScholarIQindexed works
Niels Jongs has 140 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Niels Jongs have?
ScholarIQcitation count
Niels Jongs has 3,826 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Niels Jongs?
ScholarIQh-index
Niels Jongs has an h-index of 31 in OpenAlex.
What is the i10-index of Niels Jongs?
ScholarIQi10-index
Niels Jongs has an i10-index of 48 in OpenAlex.
What is the ORCID of Niels Jongs?
ScholarIQorcid
The ORCID for Niels Jongs is on the source record.
What is the OpenAlex record for Niels Jongs?
ScholarIQopenalex
The OpenAlex for Niels Jongs is on the source record.
What are the most-cited papers on Niels Jongs?
ScholarIQmost cited works
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial
Michele Provenzano, María Jesús Puchades, Carlo Garofalo, Niels Jongs, Luis D’Marco, Michele Andreucci, Luca De Nicola, José Luis Górriz, Hiddo J.L. Heerspink